International Journal of Respiratory Medicine

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (629)348-3199

Opinion Article - International Journal of Respiratory Medicine (2023) Volume 8, Issue 5

Interstitial lung disease and connective tissue disorders: A complex relationship

Osman Guler*

Division of Pulmonary Medicine, University of Alberta, Edmonton, Alberta, Canada

*Corresponding Author:
Osman Guler
Division of Pulmonary Medicine
University of Alberta, Edmonton, Alberta, Canada

Received: 04-Oct-2023, Manuscript No. AAIJRM-23-118948; Editor assigned: 06-Oct-2023, PreQC No. AAIJRM-23-118948(PQ); Reviewed: 18-Oct-2023, QC No. AAIJRM-23-118948; Revised: 21-Oct-2023, Manuscript No. AAIJRM-23-118948(R); Published: 25-Oct-2023, DOI: 10.35841/aaijrm-8.5.173

Citation: Osman Guler. Interstitial lung disease and connective tissue disorders: A complex relationship. Int J Respir Med. 2023; 8(5):173

Visit for more related articles at International Journal of Respiratory Medicine


Interstitial lung disease (ILD) encompasses a diverse group of pulmonary disorders characterized by inflammation and fibrosis of the lung interstitium. While ILD can occur in isolation, it is frequently associated with various connective tissue disorders (CTDs), making the relationship between ILD and CTDs a complex and multifaceted one. This article explores the intricate interplay between ILD and CTDs, shedding light on the clinical manifestations, pathogenesis, and management of this challenging combination [1].

ILD associated with CTDs often presents with unique clinical features. Patients may experience progressive dyspnea, nonproductive cough, and bibasilar crackles on auscultation. Additionally, they frequently exhibit extrapulmonary manifestations specific to the underlying CTD, such as skin rashes, joint pain, or Raynaud's phenomenon. It is essential for clinicians to recognize these signs as they can guide both diagnosis and treatment [2].

A range of CTDs can be linked to ILD, with systemic sclerosis (SSc), rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE) being the most common culprits. In SSc, ILD is often a primary pulmonary manifestation, leading to significant morbidity and mortality. RA-associated ILD may develop independently of joint involvement, emphasizing the importance of vigilant lung assessment in patients with CTDs. The relationship between SLE and ILD is less well-defined but underscores the need for considering ILD in a broader spectrum of CTDs [3].

The pathogenesis of ILD in the context of CTDs is multifactorial. Autoimmunity and chronic inflammation are central players. Dysregulated immune responses, characterized by the production of autoantibodies and pro-inflammatory cytokines, contribute to the development and progression of fibrosis. Genetic factors and environmental triggers may also play a role. Endothelial dysfunction, vascular damage, and microvascular changes are common denominators in many CTDs, promoting a pro-fibrotic environment in the lung interstitium.

Diagnosing ILD in the presence of CTDs can be challenging due to overlapping clinical and radiological features. Highresolution computed tomography (HRCT) is the primary imaging modality, revealing findings such as ground-glass opacities, reticulation, and honeycombing. However, these findings can resemble those of non-specific interstitial pneumonia, complicating the diagnostic process. Lung biopsy may be necessary to differentiate between CTD-ILD and other ILD subtypes accurately [4].

Management of ILD in the context of CTDs is complex and requires a multidisciplinary approach. Treating the underlying CTD with immunosuppressive agents, such as corticosteroids and disease-modifying antirheumatic drugs, is a key component. These medications can help dampen the autoimmune response, potentially slowing the progression of ILD. For certain CTDs, novel targeted therapies, such as antifibrotic agents, are emerging as promising options.

In addition to immunosuppressive therapy, supportive care is essential. Patients with CTD-ILD benefit from pulmonary rehabilitation, supplemental oxygen, and, in advanced cases, lung transplantation. Furthermore, monitoring for disease progression through pulmonary function tests and HRCT scans is critical to adjust treatment plans as needed. The prognosis of CTD-ILD varies depending on the underlying connective tissue disorder, the extent of pulmonary involvement, and the response to treatment. In some cases, ILD may remain stable or even improve with appropriate therapy, while in others; it may progress rapidly, leading to respiratory failure. The early identification and management of ILD in the context of CTDs can significantly influence the prognosis [5].


In conclusion, the relationship between ILD and connective tissue disorders is intricate and multifaceted. The clinical manifestations, pathogenesis, and management of ILD in the context of CTDs pose unique challenges for healthcare providers. A thorough understanding of this relationship is vital to facilitate timely diagnosis and appropriate management, ultimately improving the quality of life and prognosis for affected individuals. Further research and collaborative efforts within the medical community are essential to unravel the complexities of this association and develop more effective treatment strategies for patients with CTD-ILD.


  1. Mathai SC, Danoff SK. Management of interstitial lung disease associated with connective tissue disease. Bmj. 2016;352.
  2. Indexed at, Google Scholar, Cross Ref

  3. Hao Y, Hudson M, Baron M, et al. Early mortality in a multinational systemic sclerosis inception cohort. Arthritis Rheumatol. 2017;69(5):1067-77.
  4. Indexed at, Google Scholar, Cross Ref

  5. Dougherty DH, Kwakkenbos L, Carrier ME, et al. The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. Rheumatology. 2018;57(9):1623-31.
  6. Indexed at, Google Scholar, Cross Ref

  7. Adler S, Huscher D, Siegert E, et al. Systemic sclerosis associated interstitial lung disease-individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. Arthritis Res Ther. 2018;20:1-2.
  8. Indexed at, Google Scholar, Cross Ref

  9. Chen IJ, Jan Wu YJ, Lin CW, et al. Interstitial lung disease in polymyositis and dermatomyositis. Clin Rheumatol. 2009;28(6):639-46.
  10. Indexed at, Google Scholar, Cross Ref

Get the App